Dose Escalation and Co-therapy Intensification Between Etanercept, Adalimumab, and Infliximab: The CADURA Study

Table 3: Mean total costs (2014/2015 Canadian Dollars) per patient by dose escalation and no dose escalation over 12 and 18 months.

		Total Costs¹
Cohort		No Dose Escalation over 12 Months (n=300)	Dose Escalation over 12 Months (n=14)	P-value	No Dose Escalation over 18 Months (n=207)	Dose Escalation over 18 Months (n=10)	P-value
Etanercept	N	156	0		102	0
Etanercept	Mean (SD)	$22,315 ($2,192)	-	-	$33,478 ($3,636)	-	-
Infliximab	N	20	12		17	8
Infliximab	Mean (SD)	$23,270 ($5,247)	$33,075 ($4,196)	<0.001	$33,163 ($8,822)	$49,289 ($7,661)	<0.001
Adalimumab	N	124	2		88	2
Adalimumab	Mean (SD)	$21,849 ($1,621)	$29,055 ($4,782)	0.279	$31,754 ($3,681)	$45,353 ($1,761)	<0.001

¹Total cost included drug costs and drug-related costs.